Russell Investments Group’s Adamas Pharmaceuticals ADMS Stock Holding History

Russell Investments Group’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,814	Closed	-$20K	–	3243
2020 Q4	$20K	Hold	4,814	–	–	﹤0.01%	2984
2020 Q3	$19K	Hold	4,814	–	–	﹤0.01%	3138
2020 Q2	$12K	Hold	4,814	–	–	﹤0.01%	3074
2020 Q1	$13K	Buy	4,814 +4,414	+1,104%	+$19.8K	﹤0.01%	2977
2019 Q4	$1K	Hold	400	–	–	﹤0.01%	3076
2019 Q3	$3K	Buy	+400	New	+$2.47K	﹤0.01%	3004
2018 Q1	–	Sell	-5,152	Closed	-$181K	–	3040
2017 Q4	$181K	Sell	5,152 -2,711	-34%	-$75.7K	﹤0.01%	2685
2017 Q3	$166K	Sell	7,863 -409	-5%	-$7.5K	﹤0.01%	2702
2017 Q2	$145K	Sell	8,272 -13,777	-62%	-$228K	﹤0.01%	2756
2017 Q1	$386K	Sell	22,049 -4,868	-18%	-$82.9K	﹤0.01%	2519
2016 Q4	$469K	Buy	+26,917	New	+$416K	﹤0.01%	2489

Other funds holding ADMS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCPM

Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Russell Investments Group's ADMS Position: Q1 2021 in Review

Russell Investments Group sold out of Adamas Pharmaceuticals (ADMS) in Q1 2021, closing a stake of 4,814 shares — an estimated $20K sold.

Russell Investments Group first reported a position in ADMS in Q4 2016 and held it in 11 quarters. The position peaked at $469K in Q4 2016. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2021.

Russell Investments Group reported no remaining Adamas Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Russell Investments Group sold 4,814 Adamas Pharmaceuticals shares in Q1 2021, an estimated $20K.
Russell Investments Group first reported a position in Adamas Pharmaceuticals in Q4 2016 and held it in 11 quarters.
Russell Investments Group's Adamas Pharmaceuticals position peaked at $469K in Q4 2016.
73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2021.

Based on Russell Investments Group's 13F filing for Q1 2021, filed 10 May 2021.